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Summary
Background  and  purpose:  There  have  been  no  large-scale  studies  on  the  impact  of  diabetes
mellitus (DM)  on  outcomes  in  Japanese  patients  undergoing  coronary  artery  bypass  grafting
(CABG).
Methods  and  subjects:  A  multi-institutional  retrospective  cohort  study  was  conducted  in  14
Japanese  centers.  All  adult  patients  who  underwent  isolated  CABG  from  2007  to  2008  were
included  (n  =  1522,  mean  age:  68.5  years).  The  deﬁnitions  of  DM  were  all  patients  admitted
with diagnosis  of  DM  and  preoperative  glycated  hemoglobin  (Hb)  A1c  ≥  6.5%.  Univariate  and
multivariate  analyses  were  performed  to  identify  the  risk  of  morbidity  and  mortality.
Results:  There  were  849  DM  and  572  non-DM  patients.  Preoperative  mean  HbA1c  were  7.1%  in  the
DM group  and  5.7%  in  the  non-DM  group  (p  <  0.0001).  Preoperative,  intraoperative,  and  3-day  aver-
age postoperative  blood  glucose  (BG)  were  146  mg/dl,  172  mg/dl,  and  168  mg/dl  in  the  DM  group,
and 103  mg/dl,  140  mg/dl,  and  136  mg/dl  in  the  non-DM  group  (all  p  <  0.0001).  Although  there
were no  signiﬁcant  differences  in  postoperative  cardiovascular  events,  the  incidence  of  infection
was signiﬁcantly  higher  in  the  DM  group  than  in  the  non-DM  group  (9.2%  vs  6.1%,  p  =  0.036)  on  the
univariate  analysis.  The  all-cause  death  was  also  relatively  higher  in  the  DM  group  than  in  the
non-DM group  (2.1%  vs  1.1%,  p  =  0.12),  and  this  was  likely  related  to  infection.
Conclusion:  DM  patients  had  worse  perioperative  BG  control,  higher  incidence  of  infection,
and higher  mortality  than  non-DM  patients.  These  results  indicate  that  perioperative  BG  control
guidelines should  be  standardized  to  obtain  better  surgical  outcomes  in  Japanese  DM  patients.
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(MI),  cerebrovascular  events,  acute  renal  failure,  and  other
cardiovascular  events  (including  cardiac  tamponade,  ven-
tricular  tachycardia  or  ﬁbrillation,  and  complications  afterntroduction
he  prevalence  of  diabetes  mellitus  (DM)  has  increased
ramatically  in  Western  countries  over  the  past  several
ecades,  leading  in  turn  to  increased  mortality  due  to  car-
iovascular  events  [1].  This  trend  is  also  apparent  in  Asian
ountries,  especially  in  Japan,  where  the  number  of  DM
atients  has  increased  from  6.9  million  to  8.9  million  in
he  past  decade  (a  29%  increase)  [2].  The  most  important
ife-threatening  complication  in  DM  patients  is  obviously
oronary  artery  disease  [3].  There  has  been  debate  regard-
ng  the  optimal  treatment  for  DM  patients;  some  physicians
avor  percutaneous  catheter  intervention  (PCI),  while  others
avor  coronary  artery  bypass  grafting  (CABG).  Some  stud-
es  have  shown  that  CABG  yields  better  long-term  outcomes
n  DM  patients  with  multivessel  disease  [4,5]. However,  it
s  well  known  that  patients  with  DM  who  undergo  CABG
ave  worse  early  and  late  outcomes  than  CABG  patients
ithout  DM  [6,7]. Also,  it  has  been  shown  that  intraoper-
tive  and  postoperative  blood  glucose  (BG)  control  has  a
igniﬁcant  effect  on  complications  such  as  infection  and
ortality  [8—10]. However,  there  have  been  no  large-scale
tudies  on  Japanese  DM  patients  undergoing  CABG.  To  bet-
er  understand  the  impact  of  DM  on  coronary  artery  surgery
nd  to  establish  the  optimal  BG  control  method  during  car-
iac  surgery,  we  organized  a  multicenter/multidisciplinary
esearch  group,  which  we  called  the  JMAP  study  group
Japanese  Study  to  Explore  the  Impact  of  Diabetes  on  Car-
iac  Surgery  for  Optimal  Glycemic  Control  Protocol).  Herein,
e  carried  out  a  retrospective  cohort  study  to  identify
he  impact  of  DM  and  BG  control  on  surgical  outcomes  in
apanese  patients  undergoing  CABG.aterials and methods
rom  2007  to  2008,  a  total  of  1522  patients  underwent
solated  CABG  in  14  cardiac  surgery  centers  including  10
P
s
s
ton  behalf  of  Japanese  College  of  Cardiology.
niversity  hospitals  (Appendix  I)  in  Japan.  Patients  who
nderwent  redo  CABG  were  included,  but  patients  who
nderwent  concomitant  procedures  such  as  valvular  pro-
edures,  aneurysm  repair,  arrhythmia  surgery,  repair  of
entricular  septal  perforation,  and  surgical  ventricular
estoration  procedures  were  excluded  from  this  study.  The
umber  of  the  cases  enrolled  in  each  hospital  varied  from
 to  365,  also  the  number  of  the  operating  surgeons  ranged
rom  one  to  three.  All  the  patient  characteristics  and  oper-
tive  data  were  extracted  from  the  prospective  national
atabase  (the  Japan  Adult  Cardiovascular  Surgery  Database:
ACVSD),  which  is  similar  to  the  Society  of  Thoracic  Sur-
eons  (STS)  national  database  in  North  America.  Other
tudy-speciﬁc  data  like  preoperative  glycated  hemoglobin
Hb)A1c  and  perioperative  BG  control,  as  well  as  other  blood
aboratory  data  and  postoperative  complications  including
ardiovascular  events  and  individual  infections,  which  are
ot  included  in  the  JACVSD,  were  obtained  from  medi-
al  records  at  each  study  site.  These  two  sets  of  data
ere  merged,  then  blinded,  and  sent  to  a data  center  (the
BM  Research  Center,  Kyoto  University  Graduate  School  of
edicine,  Kyoto,  Japan).
Demographic  variables  are  listed  in  Appendix  II.  Of  note,
he  Japanese  Diabetes  Society  (JDS)  value  of  HbA1c  (%)  is
onverted  into  the  National  Glycohemoglobin  Standardiza-
ion  Program  (NGSP)  equivalent  value  (%)  calculated  by  the
ollowing  formula  according  to  the  JDS  guidelines  [11]:
bA1c  (NGSP)  (%)  =  HbA1c  (JDS)  (%)  +  0.4  (%)
Postoperative  variables  were  acute  myocardial  infarctionCI).  Postoperative  infection  was  categorized  into  deep
ternal  wound  infection  (anterior  mediastinitis),  superﬁcial
ternal  wound  infection,  graft  harvesting  site  infec-
ion,  blood  stream  infection,  urinary  tract  infection,  and
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pneumonia.  Details  of  the  deﬁnitions  of  the  clinical  events
are  summarized  in  Appendix  III.  Hospital  death  included  all-
cause  death  within  30  days  of  operation  or  during  initial
hospitalization.  All  the  aforementioned  clinical  events  were
evaluated  at  the  participating  centers,  and  then  assessed
by  the  independent  clinical  events  evaluation  committee
(Appendix  IV)  if  necessary.  The  primary  composite  endpoint
was  deﬁned  as  a  composite  of  acute  MI,  cerebrovascu-
lar  accidents,  other  cardiovascular  events,  all  infections
and  their  related  deaths.  Although  cardio-cerebrovascular
events  were  thought  to  be  important  for  DM  patients,  this
prespeciﬁed  primary  composite  endpoint  was  not  related
to  DM.  Thus,  we  added  a  new  composite  endpoint  (the
additional  composite  endpoint),  which  consisted  of  all
infections,  acute  renal  failure,  and  all-cause  deaths,  and
conducted  a  post  hoc  analysis.
DM  patients  were  deﬁned  as  those  patients  who  were
admitted  to  the  participating  hospitals  with  a  diagnosis  of
DM.  Patients  without  a  previous  diagnosis  of  DM  who  had
preoperative  HbA1c  ≥  6.5%  (NGSP)  were  also  included  [12].
The  intraoperative  BG  was  an  average  of  3—4  BG  measure-
ments  taken  during  surgery.  In  the  intensive  care  unit,  the
frequency  of  BG  measurement  was  similar  among  the  partic-
ipating  hospitals:  BG  was  measured  every  2—4  h  in  patients
with  intravenous  continuous  insulin  infusion,  and  at  least  4
times  in  non-diabetic  patients  without  insulin.  The  postoper-
ative  3-day  BG  average  was  a  composite  average  of  the  daily
mean  BG  levels  (BG  was  measured  up  to  12  times  per  day  fol-
lowing  surgery)  from  the  day  of  the  surgery  to  postoperative
day  3.
Perioperative  BG  control  methods  varied  from  hospital
to  hospital,  however,  in  all  the  participating  institutions,
it  was  standard  practice  to  treat  hyperglycemia  with  con-
tinuous  insulin  infusion  whenever  BG  exceeded  200  mg/dl.
Preoperative  renal  insufﬁciency  was  deﬁned  as  an  increased
serum  creatinine  level  equal  to  or  more  than  2.0  mg/dl.  The
internal  thoracic  arteries  were  harvested  by  means  of  skele-
tonized  fashion  using  the  Harmonic  Scalpel  (Ethicon,  West
Somerville,  NJ,  USA)  in  most  of  the  participating  centers.
In  terms  of  intraoperative  steroid  use,  a  large  amount  of
steroid  (methylprednisolone  500—1000  mg)  was  primed  in  a
cardiopulmonary  bypass  circuit  in  some  centers  for  on-pump
CABG  cases.  Also,  some  surgeons  and  anesthesiologists  pre-
ferred  to  give  a  moderate  amount  of  intravenous  steroid
(methylprednisolone  125—500  mg)  immediately  after  start-
ing  off-pump  CABG  cases  to  prevent  systemic  inﬂammatory
responses.
Statistical  analyses
Baseline  characteristics  of  the  DM  and  the  non-DM  groups
are  described  as  mean  ±  standard  deviation  for  continuous
variables  and  proportions  for  categorical  variables.  p-Values
were  calculated  by  the  t-test  and  the  chi-squared  test.  We
compared  the  proportions  of  primary  and  additional  compos-
ite  endpoints  and  their  components  between  the  DM  and  the
non-DM  groups.  Risk  ratios  and  associated  95%  conﬁdence
intervals  were  calculated.
Logistic  regression  analyses  were  conducted  to  estimate
the  magnitude  of  the  effect  of  DM  on  the  additional  compos-
ite  endpoint,  all  infections,  and  all-cause  deaths  adjusted  by
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ge  (in  10-year  increments),  gender,  body  mass  index,  con-
estive  heart  failure,  renal  insufﬁciency,  chronic  obstructive
ulmonary  disease,  peripheral  artery  disease,  left  ventric-
lar  ejection  fraction  <  50%,  operative  status  (elective  vs
rgent  or  emergency),  bilateral  internal  thoracic  artery  use,
nd  intraoperative  steroid  use.  Of  note,  these  factors  were
reﬁxed  before  the  statistical  analyses.  Odds  ratios  and
heir  associated  95%  conﬁdence  intervals  were  calculated.
ll  analyses  were  performed  with  JMP  8.0  statistics  software
SAS  Institute  Inc.,  Cary,  NC,  USA).  The  two-sided  alpha  level
as  set  to  5%.
This  study  was  approved  by  the  Internal  Review  Board
t  all  the  participating  hospitals  and  the  Ethics  Commit-
ee  of  the  Kyoto  University  Graduate  School  and  Faculty  of
edicine.  All  the  patients  and  their  families  gave  written
onsent  at  the  time  of  operation  for  participation  in  the
ACVSD.
esults
 total  of  1522  enrolled  patients  were  classiﬁed  into  two
roups:  the  DM  group  (n  =  849)  and  the  non-DM  group
n  =  572).  Because  there  were  no  preoperative  HbA1c  data
or  101  patients  without  a  previous  diagnosis  of  DM,  these
atients  were  excluded  from  this  study.  The  preoperative
anagement  of  BG  in  the  DM  group  included  subcutaneous
nsulin  injection  in  254  patients  (29.9%),  oral  medications
n  342  (40.3%),  and  diet  regulation  in  233  (27.4%).  Patients’
aseline  characteristics  are  shown  in  Table  1.  There  were
o  differences  in  terms  of  age,  gender,  and  body  mass  index
BMI).  However,  depressed  left  ventricular  systolic  function
ejection  fraction  <  50%),  renal  insufﬁciency,  and  peripheral
rtery  disease  were  signiﬁcantly  higher  in  the  DM  group  than
n  the  non-DM  group.  On  the  other  hand,  chronic  obstruc-
ive  pulmonary  disease  was  less  common  in  the  DM  group.
here  was  no  difference  in  terms  of  usage  of  bilateral  inter-
al  thoracic  artery,  however  intraoperative  administration
f  intravenous  steroids  was  more  common  in  the  non-DM
roup.  There  were  no  differences  in  operative  status.  Off-
ump  technique  was  used  frequently  in  both  groups  (about
0%  of  patients  in  each  group).
Preoperative  mean  HbA1c  were  7.1%  in  the  DM  group  and
.7%  in  the  non-DM  group  (p  <  0.0001).  Also,  preoperative
asting,  intraoperative,  and  3-day  average  postoperative  BG
ere  146  mg/dl,  172  mg/dl,  and  168  mg/dl  in  the  DM  group,
nd  103  mg/dl,  140  mg/dl,  and  136  mg/dl  in  the  non-DM
roup,  respectively.  At  all  measurement  points,  DM  patients
ad  signiﬁcantly  higher  BG  levels  (p  <  0.0001).  In  terms  of
ostoperative  BG  control,  71%  of  the  patients  in  the  DM
roup  were  treated  with  continuous  insulin  infusion  whereas
nly  22%  of  the  patients  in  the  non-DM  group  were  treated
ith  continuous  insulin  infusion.  As  shown  in  Table  2,  the
ll-cause  deaths  were  2.1%  (n  =  18)  in  the  DM  group  and  1.1%
n  =  6)  in  non-DM  group  (p  =  0.124).  There  was  no  signiﬁcant
ifference  in  the  primary  composite  endpoint,  however,  the
dditional  composite  endpoint  was  signiﬁcantly  higher  in
he  DM  group.  In  terms  of  complications,  although  there
ere  no  signiﬁcant  differences  in  the  incidence  of  postoper-
tive  cardiovascular  events  and  cerebrovascular  accidents,
he  incidence  of  overall  infection  was  signiﬁcantly  higher
n  the  DM  group  than  in  the  non-DM  group  (9.2%  vs  6.1%,
278  K.  Minakata  et  al.
Table  1  Patients’  baseline  characteristics.
Variables  DM  group  (n  =  849)  Non-DM  group  (n  =  572)  p-Value
Mean  age  (SD)  68.6  (8.4)  68.0  (10.1)  0.282
Age ≥  75  208  (24.5%)  162  (28.3%)  0.107
Male gender  649  (76.4%)  451  (78.9%)  0.288
Preoperative  HbA1c  (SD)  7.1%  (1.2)  5.7%  (0.4)  <0.0001
Mean body  mass  index  (SD)  23.7  (3.3)  23.4  (3.1)  0.094
Preoperative  steroid  use 18  (2.1%)  8  (1.4%)  0.320
Congestive heart  failure 131 (15.5%)  98  (17.1%)  0.397
Renal insufﬁciency 117 (13.8%)  45 (7.9%)  0.001
Chronic obstructive  pulmonary  disease 57 (6.7%)  64 (11.2%)  0.003
Peripheral artery  disease 193 (22.7%)  101 (17.7%)  0.021
Left ventricular  ejection  fraction  <  50%  212  (26.6%)  115  (20.5%)  0.010
Operative status
Elective  732  (86.2%)  484  (84.6%)  0.154
Urgent 76  (9.0%)  67  (11.7%)
Emergency  41  (4.8%)  21  (3.7%)
Bilateral  internal  thoracic  artery  use  400  (47.1%)  285  (49.8%)  0.316
Intraoperative  steroid  use  246  (29.0%)  200  (35.0%)  0.017
On-pump or  off-pump
On-pump  214  (25.2%)  154  (26.9%)  0.754
On-pump beating  43  (5.1%)  27  (4.7%)
)  
p
i
n
cOff-pump  592  (69.7%
DM, diabetes mellitus; HbA1c, glycated hemoglobin A1c. =  0.036).  In  particular,  the  incidence  of  deep  sternal  wound
nfection  was  higher  in  the  DM  group  (2.0%)  than  in  the
on-DM  group  (1.1%)  although  this  did  not  reach  statisti-
al  signiﬁcance  (p  =  0.163).  The  cause  of  death  in  the  DM
g
w
d
s
Table  2  Adverse  events  and  outcomes.
DM  group  (n  =  849)  No
Primary  composite  endpointa 105  (12.4%)  60
Additional composite  endpointb 92  (10.8%)  42
All-cause deaths  18  (2.1%)  6  (
Acute myocardial  infarction  11  (1.3%)  12
Related death  2  (0.2%)  0  
Cerebrovascular  accident  12  (1.4%)  6  (
Related death  1  (0.1%)  0
Other cardiovascular  event  11  (1.3%)  15
Related death 3  (0.4%)  1  (
All infections  78  (9.2%)  35
Related death 10  (1.2%)  1  (
Infection  site
Deep  sternal  wound 17 (2.0%)  6 (
Superﬁcial sternal  wound  22  (2.6%)  15
Graft harvest  site  22  (2.6%)  9  (
Blood stream  5  (0.6%)  2  (
Urinary  tract  5  (0.6%)  1  (
Pneumonia  9  (1.1%)  8  (
Acute renal  failure  12  (1.4%)  5  (
Related death  1  (0.1%)  0
Other deaths  1  (0.1%)  4  (
CI, conﬁdence interval; DM, diabetes mellitus; NA, not available due t
a Primary composite endpoint consisted of acute myocardial infarction
infection and their related deaths.
b Additional composite endpoint consisted of overall infection, acute391  (68.4%)roup  was  predominantly  related  to  infection  (10/18:  56%),
hile  in  the  non-DM  group  there  was  only  one  patient  who
ied  of  infection  (1/6:  17%).  On  multivariate  logistic  regres-
ion  analyses,  the  statistically  signiﬁcant  risk  factors  for  the
n-DM  group  (n  =  572)  Risk  ratio  (95%  CI)  p-Value
 (10.5%)  1.18  (0.87—1.59)  0.279
 (7.3%)  1.48  (1.04—2.09)  0.027
1.1%)  2.02  (0.81—5.06)  0.124
 (2.1%)  NA
NA
1.1%)  NA
 (2.6%)  NA
0.2%)
 (6.1%)  1.50  (1.02—2.21)  0.036
0.2%)
1.1%)  1.91  (0.76—4.81)  0.163
 (2.6%)
1.6%)
0.4%)
0.2%)
1.1%)
0.9%)  1.62  (0.57—4.57)  0.359
0.7%)  NA
o too few events.
, cerebrovascular accidents, other cardiovascular events, overall
 renal failure, and all-cause deaths.
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Table  3  Multivariate  logistic  regression  analysis  for  the  primary  composite  endpoint.a
Variables  Odds  ratio  95%  CI  p-Value
Diabetes  mellitus  1.07  0.75—1.53  0.715
Age (in  10-year  increments)  1.01  0.83—1.23  0.915
Male gender  0.58  0.40—0.86  0.006
Body mass  index  (in  1  kg/m2 increments)  1.04  0.98—1.09  0.164
Congestive heart  failure  1.01  0.58—1.70  0.985
Renal insufﬁciency 2.18  1.36—3.43  0.001
Chronic obstructive  pulmonary  disease 1.73  0.98—2.95  0.051
Peripheral artery  disease 1.12  0.73—1.69  0.585
Left ventricular  ejection  fraction  <  50% 1.25  0.83—1.86 0.268
Urgent 1.71  0.95—2.97 0.065
Emergency  0.79  0.22—2.24  0.689
Bilateral internal  thoracic  artery  use  1.34  0.94—1.91  0.105
Intraoperative  steroid  use  0.72  0.49—1.06  0.100
CI, conﬁdence interval.
a Primary composite endpoint consisted of acute myocardial infarction, cerebrovascular accidents, other cardiovascular events, overall
infection and their related deaths.
Table  4  Multivariate  logistic  regression  analysis  for  the  additional  composite  endpoint.a
Variables  Odds  ratio  95%  CI  p-Value
Diabetes  mellitus  1.28  0.85—1.92  0.235
Age (in  10-year  increments)  1.01  0.81—1.26  0.935
Male gender  0.58  0.38—0.89  0.012
Body mass  index  (in  1  kg/m2 increments)  1.07  1.02—1.14  0.012
Congestive heart  failure  0.94  0.51—1.67  0.843
Renal insufﬁciency  3.23  2.00—5.14  0.000
Chronic obstructive  pulmonary  disease  1.91  1.02—3.41  0.034
Peripheral artery  disease  0.94  0.57—1.49  0.787
Left ventricular  ejection  fraction  <  50%  1.39  0.89—2.13  0.139
Urgent 1.60  0.82—2.95  0.149
Emergency 1.13  0.34—3.13  0.823
Bilateral internal  thoracic  artery  use  1.31  0.89—1.94  0.177
Intraoperative  steroid  use  0.66  0.42—1.01  0.060
CI, conﬁdence interval.
a Additional composite endpoint consisted of overall infection, acute renal failure, and all-cause death.
Table  5  Multivariate  logistic  regression  analysis  for  all  infections.
Variables  Odds  ratio  95%  CI  p-Value
Diabetes  mellitus 1.29  0.84—2.01  0.253
Age (in  10-year  increments)  0.96  0.76—1.22  0.751
Male gender  0.52  0.33—0.83  0.005
Body mass  index  (in  1  kg/m2 increments)  1.08  1.02—1.14  0.014
Congestive heart  failure  0.96  0.49—1.79  0.904
Renal insufﬁciency  3.13  1.86—5.16  0.000
Chronic obstructive  pulmonary  disease  1.85  0.93—3.46  0.064
Peripheral artery  disease  0.85  0.49—1.40  0.533
Left ventricular  ejection  fraction  <  50%  1.42  0.88—2.26  0.142
Urgent 1.37  0.65—2.69  0.386
Emergency 0.72  0.16—2.36  0.619
Bilateral internal  thoracic  artery  use  1.37  0.90—2.09  0.144
Intraoperative  steroid  use  0.68  0.42—1.06  0.099
CI, conﬁdence interval.
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Table  6  Multivariate  logistic  regression  analysis  for  all-cause  death.
Variables  Odds  ratio  95%  CI  p-Value
Diabetes  mellitus  1.89  0.72—5.61  0.219
Age (in  10-year  increments)  1.10  0.67—1.88  0.715
Male gender  0.66  0.25—1.97  0.429
Body mass  index  (in  1  kg/m2 increments)  0.90  0.78—1.04  0.169
Congestive heart  failure  2.27  0.69—7.03  0.165
Renal insufﬁciency 3.04  1.12—7.80  0.023
Chronic obstructive  pulmonary  disease 4.22  1.24—12.60  0.013
Peripheral artery  disease 1.56  0.55—4.07  0.374
Left ventricular  ejection  fraction  <  50% 2.33  0.92—5.87 0.071
Urgent 3.15  0.89—10.32 0.065
Emergency  5.30  1.05—26.7  0.043
Bilateral internal  thoracic  artery  use  1.85  0.71—4.81  0.204
Intraoperative  steroid  use  0.35  0.10—1.00  0.073
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rimary  composite  endpoint  included  female  gender  and
enal  insufﬁciency  (Table  3).  The  statistically  signiﬁcant
isk  factors  for  the  additional  composite  endpoint  included
emale  gender,  BMI,  renal  insufﬁciency,  and  chronic  obstruc-
ive  pulmonary  disease  (Table  4).  Also,  the  statistically
igniﬁcant  risk  factors  for  overall  infection  were  female
ender,  BMI,  and  renal  insufﬁciency  (Table  5).  Finally,  the
tatistically  signiﬁcant  preoperative  or  operative  risk  fac-
ors  for  all-cause  death  were  renal  insufﬁciency,  congestive
eart  failure,  and  emergency  surgery  (Table  6).  The  pres-
nce  of  DM  was  not  identiﬁed  as  a  statistically  signiﬁcant
ndependent  risk  factor  on  multivariate  analyses  for  the
omposite  endpoints  and  complications  including  overall
nfection  and  all-cause  death  which  were  linked  to  DM  on
he  univariate  analyses.  On  the  other  hand,  it  became  appar-
nt  that  preoperative  renal  insufﬁciency  was  a  very  strong
ommon  risk  factor  for  both  overall  infection  and  all-cause
eath.
iscussion
n  2009,  the  Society  of  Thoracic  Surgeons  Blood  Glucose
anagement  Task  Force  published  their  guidelines  regarding
G  management  during  adult  cardiac  surgery  [13]. Accord-
ng  to  these  guidelines,  it  is  highly  desirable  to  maintain
G  <  180  mg/dl  during  surgery  and  during  the  immediate
ostoperative  period  with  intravenous  insulin  infusion  in  DM
atients.  Although  it  is  unnecessary  to  use  intravenous  con-
inuous  insulin  infusion  in  non-DM  patients  during  surgery,
oth  DM  and  non-DM  patients  beneﬁt  from  maintaining
G  <  180  mg/dl  in  order  to  prevent  morbidity  and  mortality
13].  This  begs  the  question  of  how  low  the  target  should
e.  Furnary  et  al.  reported  from  their  prospective  observa-
ional  study  that  there  was  a  highly  signiﬁcant  relationship
etween  mortality  and  postoperative  glucose  levels  rising
bove  175  mg/dl  [10]. Our  current  BG  levels  in  DM  patients
ere  barely  below  this  cut-off  value,  given  the  intraoper-
tive  and  postoperative  3-day  average  BG  were  172  mg/dl
nd  168  mg/dl,  respectively.  Therefore,  there  seemed  to  be
ome  room  to  lower  the  BG  levels  further,  which  potentially
r
(
l
8ould  reduce  the  morbidity  and  the  mortality  in  the  DM
atients.
It  has  been  reported  that  the  presence  of  DM  in  patients
ndergoing  CABG  is  a  signiﬁcant  risk  factor  for  hospital  mor-
ality  and  morbidity  including  stroke,  deep  sternal  wound
nfection,  and  length  of  hospital  stay  from  the  STS  database
nalyses  [14]. In  addition,  DM  patients  have  worse  long-term
urvival  than  non-DM  patients  after  surgery  [6].  Our  results
rom  univariate  analyses  show  that  DM  has  a signiﬁcant  inﬂu-
nce  on  the  additional  composite  endpoint  consisting  of
ll-cause  death,  overall  infection,  and  acute  renal  failure
10.8%  vs  7.3%,  p  =  0.027).  Looking  at  each  complication,
verall  infection  was  the  most  signiﬁcant  factor  contribut-
ng  to  this  result  (9.2%  in  DM  group  vs  6.1%  in  non-DM  group,
 =  0.036).  Also,  DM  patients  tended  to  have  higher  mortal-
ty  than  non-DM  patients  (2.1%  vs  1.1%,  p  =  0.124).  Moreover,
M  patients  tended  to  have  a  much  higher  incidence  of  deep
ternal  wound  infection  than  non-DM  patients  (2.0%  vs  1.1%,
 =  0.163),  although  this  difference  did  not  reach  statistical
igniﬁcance.  However,  the  complication  of  infection  deﬁ-
itely  inﬂuenced  mortality  rates  because  the  majority  of
eaths  were  related  to  infection  in  the  DM  group.  There  is
o  doubt  that  DM  patients  have  unfavorable  baseline  charac-
eristics  such  as  diffuse  coronary  artery  disease,  peripheral
rtery  disease,  high  BMI,  and  worse  preoperative  renal  func-
ion,  all  of  which  would  contribute  to  worse  short-  and
ong-term  outcomes  compared  to  non-DM  patients.
Our  multivariate  logistic  regression  analyses  failed  to
dentify  DM  as  an  independent  risk  factor  for  any  of  the  com-
lications  including  overall  infection  and  all-cause  death.
his  is  most  likely  because  some  other  preoperative  risk  fac-
ors  such  as  renal  insufﬁciency  (predominantly  in  the  DM
roup)  and  chronic  obstructive  pulmonary  disease  (predom-
nantly  in  the  non-DM  group)  had  too  much  inﬂuence  to  each
ndpoint,  which  attenuated  the  impact  of  the  presence  of
M.  This  is  one  of  the  well-known  downsides  of  the  logistic
egression  models.  In  fact,  the  prevalence  of  preoperative
enal  insufﬁciency  in  this  study  population  is  much  higher
13.8%  in  the  DM  group)  than  that  of  other  studies  pub-
ished  in  the  literature  [10]. It  should  also  be  noted  that
5  patients  (5.6%  of  all  study  patients)  predominantly  in  the
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DImpact  of  DM  on  outcomes  of  CABG  
DM  group  had  been  on  chronic  hemodialysis  preoperatively,
which  must  have  given  great  impact  to  the  multivariate  anal-
yses.  We  are  now  in  the  process  of  doing  a  sub-analysis  in
this  regard  to  identify  the  relative  impact  of  the  presence
of  preoperative  renal  insufﬁciency.
The  Portland  Diabetic  Project,  which  is  an  on-going
prospective  study  of  over  5000  DM  patients,  aims  to  show
that  tight  glucose  control  from  the  end  of  surgery  until  the
2nd  postoperative  day  with  continuous  insulin  infusion  may
eliminate  the  diabetic  disadvantage  [15]. They  showed  that
tight  glucose  control  with  a  full  3  days  of  continuous  insulin
infusion  (the  Portland  Protocol)  signiﬁcantly  reduced  mor-
tality  (by  65%),  deep  sternal  wound  infection  (by  63%),  and
length  of  hospital  stay  (average  2-day  reduction).  Therefore,
they  concluded  that  DM  is  not  the  true  risk  factor  for  the
seemingly  unfair  diabetic  disadvantage  in  terms  of  increased
mortality  and  morbidity.  Since  we  showed  that  DM  patients
still  have  excess  mortality  and  morbidity  compared  to  non-
DM  patients  in  the  current  study,  we  might  be  able  to  reduce
these  excess  complications  by  implementing  tighter  glucose
control  protocols.
It has  been  debated  whether  intensive  BG  control  is  bet-
ter  than  conventional  BG  control.  In  a  landmark  paper,  van
den  Berghe  et  al.  conducted  the  ﬁrst  prospective  random-
ized  trial  comparing  tight  BG  control  (target  80—110  mg/dl)
with  intensive  insulin  therapy  to  conventional  BG  control
in  critically  ill  surgical  patients  [16]. They  demonstrated
that  tight  BG  control  resulted  in  a  signiﬁcant  reduction  in
mortality  (10.6%  with  intensive  treatment  vs  20.2%  with
conventional  treatment,  p  =  0.005),  exclusively  in  those
patients  who  required  ≥5  days  of  intensive  care  unit  (ICU)
care  with  multiorgan  failure  and  sepsis.  Also,  cardiac  sur-
gical  mortality  was  reduced  in  those  patients  requiring
≥3  days  of  ICU  care.  D’Alessandro  et  al.  reported  a  propen-
sity  analysis  that  showed  that  strict  BG  control  signiﬁcantly
reduced  the  EuroSCORE  expected  mortality  in  DM  patients
undergoing  CABG,  especially  in  moderate-  to  high-risk
patients  [17]. Their  BG  target  in  the  operating  room  and  ICU
were  150—200  mg/dl  and  ≤140  mg/dl,  respectively.  In  terms
of  long-term  outcomes,  Lazar  et  al.  showed  that  tight  peri-
operative  glucose  control  with  glucose-insulin-potassium
solution  improved  not  only  perioperative  outcomes,  but  also
long-term  survival  and  freedom  from  recurrent  angina  [18].
These  studies  clearly  demonstrate  the  superiority  of  tight
BG  control  over  conventional  control,  especially  in  critically
ill  patients.  On  the  other  hand,  Gandhi  et  al.  showed  in  a
prospective  randomized  study  on  400  patients  undergoing
CABG,  including  non-DM  patients,  that  intraoperative  inten-
sive  insulin  therapy  with  a  target  range  of  80—100  mg/dl
did  not  reduce  perioperative  mortality  and  morbidity,  but
rather  increased  stroke  rate  and  mortality  [19]. Further-
more,  a  meta-analysis  of  29  randomized  studies  focusing  on
the  beneﬁts  and  risks  of  tight  glucose  control  in  critically
ill  adult  patients  concluded  that  tight  glucose  control  was
not  associated  with  signiﬁcantly  reduced  hospital  mortality
but  was  associated  with  an  increased  risk  of  hypoglycemia
[20].  To  support  these  results,  a  recent  prospective  random-
ized  multicenter  trial  (the  NICE-SUGAR  study)  demonstrated
that  intensive  BG  control  with  a  target  of  81—108  mg/dl
increased  mortality  among  adults  in  the  ICU  compared
with  conventional  BG  control  with  a  target  of  180  mg/dl
or  less  [21]. In  this  study,  however,  the  mortalities  in  the
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ntensive  control  group  and  conventional  control  group  were
7.5%  and  24.9%  at  90  days  after  randomization,  respec-
ively.  In  both  groups,  potentially  life-sustaining  treatments
ere  withheld  or  withdrawn  in  more  than  90%  of  the  patients
ho  died.  Also,  it  seems  that  severe  hypoglycemia  com-
only  occurred  in  the  intensive  BG  control  group  of  the
tudy,  which  may  raise  the  question  of  the  safety  and  fea-
ibility  of  the  tight  glucose  control  protocol  itself.  Because
hese  patients  in  the  study  were  so  sick  at  the  time  of  enroll-
ent,  it  is  difﬁcult  to  compare  the  results  of  these  studies
ith  studies  on  regular  cardiac  surgery  patients,  given  the
urrent  acceptable  mortality  after  CABG  of  around  1—2%.
t  may  be  necessary  to  conduct  a  prospective  randomized
tudy  to  compare  tight  glucose  control  and  conventional
lucose  control  using  more  sophisticated  protocols  with  a
inimum  risk  of  hypoglycemia  in  exclusively  cardiac  surgery
atients  to  reach  a  deﬁnitive  conclusion,  which  we  are  cur-
ently  planning  to  initiate  as  a next  step  to  our  ultimate
oal.
Perhaps,  one  of  the  other  interesting  features  of  this
ulti-center  study  is  the  fact  that  about  70%  of  all  iso-
ated  CABG  procedures  were  performed  using  the  off-pump
echnique  in  both  the  DM  and  non-DM  groups.  This  trend
s  far  above  the  typical  rates  in  North  America,  given
he  fact  that  the  adoption  of  off-pump  CABG  was  only
1.8%  in  2009  according  to  the  STS  database  [22]. A
ystematic  review  and  meta-analysis  of  propensity  score
nalyses  in  more  than  123,000  patients  comparing  off-
ump  and  on-pump  CABG  demonstrated  that  off-pump
rovides  favorable  outcomes  in  mortality,  stroke,  renal
ailure,  wound  infection,  blood  transfusion,  intraaortic
alloon  pump  support,  and  prolonged  ventilation  [23].
t  will  be  interesting  to  see  the  impact  of  off-pump
echniques  in  DM  patients  in  terms  of  not  only  preoper-
tive,  intraoperative,  and  postoperative  glucose  control,
ut  also  in  terms  of  postoperative  complications  and
elated  mortality  [24]. We  are  also  planning  to  perform
 post  hoc  subgroup  analysis  focusing  on  this  in  the  near
uture.
There  are  several  limitations  to  this  study.  This  was  a  ret-
ospective,  observational  study,  and  hence  unknown  patient
election  processes  may  cause  a  bias.  Importantly,  there
as  no  standard  BG  control  protocol  across  the  participat-
ng  hospitals.  Our  sample  size  was  relatively  large,  however,
t  was  not  large  enough  to  stratify  the  level  of  perioper-
tive  BG  control  as  an  indicator  of  risk  events.  In  fact,
e  were  unable  to  show  any  difference  in  terms  of  the
orbidity  and  mortality  according  to  the  level  of  intra-
perative  and  postoperative  BG  control  due  to  too  few
omplications.
onclusions
M  patients  had  poor  perioperative  BG  control  and  higher
ncidence  of  infection  with  a  higher  mortality  rate  than  non-
M  patients.  These  results  highlight  the  need  to  initiate
rospective  studies  to  standardize  perioperative  BG  control
rotocols  to  obtain  strict  BG  control,  which  may  yield  bet-
er  surgical  outcomes  in  Japanese  DM  patients  undergoing
ardiac  surgery.
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ppendix I. The list of the participating
urgical centers
wate  Medical  University  Hospital,  Sakakibara  Heart  Insti-
ute,  Jichi  Medical  University  Hospital,  Nagoya  University
ospital,  Handa  City  Hospital,  University  Hospital  of  Kyoto
refectural  University  of  Medicine,  Kyoto  University  Hos-
ital,  Tominaga  Hospital,  Wakayama  Medical  University
ospital,  Kobe  University  Hospital,  Kobe  City  Medical
enter  General  Hospital,  Kawasaki  Medical  School  Hos-
ital,  Kurume  University  Hospital,  Kagoshima  University
ospital.
ppendix II.
reoperative  variables  include  age,  gender,  height,  and
eight.  Preoperative  co-morbidities  included  systemic
ypertension,  dyslipidemia,  insulin-controlled  diabetes  mel-
itus  (DM),  oral  medication-controlled  DM,  diet-controlled-
M,  congestive  heart  failure,  renal  insufﬁciency,  chronic
bstructive  pulmonary  disease,  peripheral  artery  disease,
igarette  smoking,  cerebrovascular  accidents,  and  advanced
ew  York  Heart  Association  functional  class.  Cardiovascular
ariables  included  left  main  coronary  disease,  number  of  dis-
ased  coronary  arteries,  left  ventricular  ejection  fraction,
nstable  angina,  acute  myocardial  infarction  (MI),  previous
I,  history  of  atrial  ﬁbrillation  and  ventricular  tachycar-
ia  or  ﬁbrillation,  cardiogenic  shock,  percutaneous  coronary
ntervention,  and  intra-aortic  balloon  pump  insertion.  Pre-
perative  blood  laboratory  variables  included  random  and
asting  serum  glucose,  glycated  hemoglobin  A1c,  albumin,
erum  creatinine,  blood  urea  nitrogen,  total  cholesterol,
igh-density  and  low-density  lipoproteins,  triglycerides,
nd  C-reactive  protein.  Preoperative  medications  included
igitalis,  beta-blockers,  nitrates,  inotropic  agents,  oral
ypoglycemics,  insulin,  diuretics,  steroids,  and  immunosup-
ressants.  Intraoperative  variables  were  operative  status
elective,  urgent,  or  emergency),  reoperative  procedure,
ingle  or  bilateral  internal  thoracic  artery  or  other  arte-
ial  conduit  usage,  saphenous  vein  grafts  and  their  targets,
se  of  cardiopulmonary  bypass,  application  of  aortic  cross-
lamping,  aortic  cross-clamp  time,  cardiopulmonary  bypass
ime,  administration  of  intravenous  insulin  and  steroids,  and
lood  transfusion.K.  Minakata  et  al.
ppendix III. Deﬁnitions of clinical events
cute  myocardial  infarction: the  presence  of  at  least  two  of
he  following  symptoms  or  ﬁndings:
1)  Creatine  kinase  (CK)-MB  ≥  5%  of  total  CK  and  total
CK  ≥  3×  normal  control,  or  CK-MB  ≥  100  mg/dl.
2)  Typical  symptoms.
3)  Typical  electrocardiographic  (ECG)  change  (new  onset  of
ST-T  change  in  more  than  2  consecutive  leads  on  12-lead
ECG  or  abnormal  Q  wave).
4)  New  onset  abnormal  wall  motion  abnormality  lasting
≥24  h  on  echocardiography.
Of  note,  a  pathological  diagnosis  of  acute  MI  on  autopsy
oes  not  require  any  of  the  above  ﬁndings.
Cerebral  infarction: including  all  the  following  symptoms
nd  ﬁndings:
1)  Apparent  focal  neurological  deﬁcits  and  symptoms  or
signs  compatible  with  no  other  identiﬁed  causes.
2)  Neurological  symptoms  and  signs  lasting  ≥24  h
(excluded  if  patient  died).
3)  Radiological  diagnosis  on  computed  tomography  or  mag-
netic  resonance  image.
Acute  renal  failure:  increased  creatinine  of  more  than
wice  the  preoperative  baseline  and  equal  to  or  more  than
.0  mg/dl,  or  newly  requiring  hemodialysis.
Infection:  infection  occurs  within  30  days  after  surgery
.  Deep  sternal  wound  infection:  infection  involving  deep
sternum  and/or  anterior  mediastinum  (fascia,  sternum,
mediastinum)  and  either:
(1) Purulent  drainage  from  the  deep  incision  or  the  chest
tube  which  is  placed  in  the  area  communicating  to
the  anterior  mediastinum.
(2) Organisms  isolated  from  an  aseptically  obtained  cul-
ture  of  ﬂuid  or  tissue  from  the  deep  sternal  wound
or  anterior  mediastinum.
(3) A  deep  incision  spontaneously  dehisces  or  is  deliber-
ately  opened  by  a  surgeon  when  the  patient  has  at
least  one  of  the  following  signs  or  symptoms:  fever
(>38 ◦C),  localized  pain,  or  tenderness,  unless  site  is
culture-negative.
(4)  An  abscess  or  other  evidence  of  infection  involving
the  deep  incision  is  found  on  direct  examination,  dur-
ing  reoperation,  or  by  histopathologic  or  radiologic
examination.
(5)  Diagnosis  of  a  deep  incisional  surgical  site  infection
by  a  surgeon  or  attending  physician.
.  Superﬁcial  sternal  wound  infection:  infection  involving
only  the  skin  or  subcutaneous  tissue  of  the  incision  and
either:
(1)  Purulent  drainage,  with  or  without  laboratory  con-
ﬁrmation,  from  the  superﬁcial  incision.
(2)  Organisms  isolated  from  an  aseptically  obtained  cul-ture  of  ﬂuid  or  tissue  from  the  superﬁcial  incision.
(3)  At  least  one  of  the  following  signs  or  symp-
toms  of  infection:  pain  or  tenderness,  localized
swelling,  redness,  or  heat  and  superﬁcial  incision  is
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deliberately  opened  by  surgeon,  unless  the  incision
is  culture-negative.
(4) Diagnosis  of  superﬁcial  incisional  surgical  site  infec-
tion  by  the  surgeon  or  attending  physician.
3.  Graft  harvest  site  infection:  surgical  site(s)  infection
including  saphenous  vein  and  radial  artery  harvesting:
(1)  At  least  one  of  the  following  signs  or  symptoms
of  infection:  pain  or  tenderness,  localized  swelling,
redness,  or  heat.
(2)  Superﬁcial  incision  is  deliberately  opened  by  the  sur-
geon,  or  required  resection  of  tissue  or  drainage,
unless  the  incision  is  culture-negative.
(3) Diagnosis  of  superﬁcial  incisional  surgical  site  infec-
tion  by  the  surgeon  or  attending  physician.
4. Blood  stream  infection:  the  presence  of  a  positive  non-
contaminated  blood  culture.
Contamination  is  diagnosed  if  one  or  more  of  the  fol-
lowing  organisms  is  identiﬁed  in  only  one  of  a  series  of
blood  cultures:  coagulase-negative  staphylococci;  Pro-
pionibacterium  acnes; Micrococcus  species;  ‘‘viridans’’-
group  streptococci;  Corynebacterium  species;  or  Bacillus
species.
5. Urinary  tract  infection:  deﬁned  as  the  presence  of  symp-
toms  or  signs  compatible  with  no  other  identiﬁed  source
of  infection  along  with  either:
(1) >105/mm3 colony  forming  units/ml  of  at  least  one
bacterial  species  in  a  single  urine  specimen.
(2) purulent  urine  (>10  white  blood  cells/ﬁeld  in  a
microscopic  urinalysis).
6.  Pneumonia: The  clinical  suspicion  of  pneumonia  is  based
on  clinical  criteria;  new  or  progressive  radiological  pul-
monary  inﬁltrate  plus  more  than  two  of  the  following
characteristics:  temperature  (38 ◦C  <  or  <  35.5 ◦C),  leuko-
cyte  count  (>12,000  cells/mm3 or  <4000  cells/mm3)  or
purulent  respiratory  secretions.  Ventilator-associated
pneumonia  is  diagnosed  in  patients  with  microbiologic
evaluation  including  the  collection  of  at  least  one  lower
respiratory  airway  sample  by  sputum,  tracheobronchial
aspirate,  bronchoscopy  or  by  blind  bronchoalveolar
lavage.  Blood  cultures  and  cultures  of  pleural  ﬂuid  spec-
imens,  if  puncture  was  indicated,  were  also  undertaken.
Microbiologic  conﬁrmation  of  pneumonia  was  deﬁned
by  the  presence  of  ≥1  potentially  pathogenic  microor-
ganism  in  the  respiratory  samples  above  the  predeﬁne
thresholds  (for  bronchoalveolar  lavage  specimens,  >104
colony  forming  units/ml;  for  sputum  or  tracheobronchial
aspirate  specimens,  >105 colony  forming  units/ml);  in
pleural  ﬂuid  specimens;  or  in  blood  cultures,  if  an  alter-
native  cause  of  bacteremia  was  ruled  out.
Appendix IV.
Other  investigators: Yoshino  Mitsunaga  (Iwate  Medical
University),  Shigefumi  Matsuyama  (Sakakibara  Heart  Insti-
tute),  Shin-ichi  Mizutani  (Nagoya  University  Graduate  School
of  Medicine),  Akira  Fujimoto,  Mariko  Nakamoto,  Masami
Fukutomi,  Koji  Oba  (Kyoto  University  Graduate  School
of  Medicine),  Kiyoshi  Doi  (Kyoto  Prefectural  University
of  Medicine),  Yuki  Okamoto  (Tominaga  Hospital),  Ken-
taro  Honda  (Wakayama  Medical  University),  Kenji  Okada
(Kobe  University  Graduate  School  of  Medicine),  Yu  Shomura
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Kobe  City  Medical  Center  General  Hospital),  Eiichi  Tejima
Kawasaki  Medical  School),  Masahiro  Ueno  (Kagoshima
niversity  Graduate  School  of  Medicine  and  Dental
cience).
Independent  Clinical  Events  Evaluation  Committee:
utaka  Ohiso,  MD,  PhD,  Toyoaki  Murohara,  MD,  PhD  (Nagoya
niversity  Graduate  School  of  Medicine),  Kohei  Kaku,  MD,
hD,  Kazumi  Kimura,  MD,  PhD,  Kiyoshi  Yoshida,  MD,  PhD
Kawasaki  Medical  School),  Kazuo  Kimura,  MD,  PhD  (Yoko-
ama  City  University),  Yutaka  Furukawa,  MD,  PhD  (Kobe  City
edical  Center  General  Hospital),  Kotaro  Mitsutake,  MD,  PhD
Saitama  Medical  University).
External  Advisory  Board: Soichiro  Kitamura,  MD,  PhD
National  Cerebral  and  Cardiovascular  Center),  Hiroo  Imura,
D,  PhD  (Foundation  for  Biomedical  Research  and  Innova-
ion),  Masato  Kasuga,  MD,  PhD  (National  Center  for  Global
ealth  and  Medicine),  Haruhiko  Kikuchi,  MD,  PhD  (Kobe  City
edical  Center  General  Hospital),  Ryozo  Nagai,  MD,  PhD
University  of  Tokyo),  Yoshio  Yazaki,  MD,  PhD  (National  Hos-
ital  Organization),  Anthony  P.  Furnary,  MD  (Providence  St.
incent  Medical  Center,  Portland,  OR,  USA).
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